๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Belagavi
Clinical trial register · India

Clinical Trials in Belagavi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
91 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Belagavi, Nagpur, Pune, New Delhi, Dehradun, Kolkata, Ahemdabad, Bangalore
2026-12-16
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Vadodara, Badsa, Gurgaon, Belagavi, Pune, Mohali, Chennai
2026-09-30
Not yet open
Breastfeeding Education Support Tool
NCT06797063Breastfeeding, Exclusive, Infant Development, Infant Growth, Breast Feeding
Thomas Jefferson University
Not applicable
336
Belagavi
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Belagavi, Calicut, Coimbatore, Dehradun, Delhi, Hyderabad, Jaipur, Kanpur
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Aligarh, Bangalore, Belagavi, Bhubaneswar, Calicut, Chennai, Dehradun, Delhi
2026-08-21
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Bangalore, Belagavi, Chennai, Coimbatore, Guntur, Hyderabad, Indore, Kochi
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
AstraZeneca
Phase 3
900
Aligarh, Belagavi, Belgavi, Calicut, Chennai, Coimbatore, Delhi, Guntur
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Bangalore, Belagavi, Calicut, Chennai, Coimbatore, Guwahati, Indore, Jaipur
2026-07-06
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
AstraZeneca
Phase 3
4,500
Bangalore, Belagavi, Bikaner, Delhi, Guntur, Hyderabad, Jaipur, Jodhpur
2026-06-29
Recruiting
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
NCT07653100Respiratory Syncytial Virus (RSV)
Pfizer
Phase 3
540
Visakhapatnam, Bangalore, Belagavi, Nashik, Dwarka, New Delhi, Jaipur, Chengalpattu
2026-06-22
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
Takeda
Phase 2
222
Belagavi, Kochi, Ludhiana, Kolkata, New Delhi
2026-05-17
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals
Phase 3
5,700
Guntur, Ahmedabad, Vadodara, Belagavi, Mangalore, Manipal, Kochi, Nagpur
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Guntur, Vijayawada, Raipur, Vadodara, Gurgaon, Gurugram, Bangalore, Belagavi
2026-05-11
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Guntur, Guwahati, Bangalore, Belagavi, Calicut, Kochi, Thiruvananthapuram, Indore
2026-05-06
Recruiting
Caffeine for Hypoxic Ischemic Encephalopathy
NCT06855108Hypoxic Ischemic Encephalopathy (HIE)
NICHD Global Network for Women's and Children's Health
Phase 3
830
Belagavi, Nagpur
2026-04-08
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Allahฤbฤd, Belagavi, Belgavi, Hyderabad, Jaipur, Kochi, Lucknow, Mumbai
2026-03-26
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
Novartis Pharmaceuticals
Phase 2
210
Ahmedabad, Bangalore, Belagavi, Mysore, Nashik
2026-03-09
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
Boehringer Ingelheim
Phase 3
1,325
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Bikaner, Calicut, Chandigarh, Coimbatore
2026-02-17
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
Phase 2/3
1,156
Belagavi, Thane, New Delhi, Ajmer, Jaipur, Coimbatore, Hyderabad, Dehradun
2026-02-11
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
NCT06723392Preterm Birth, Small for Gestational Age (SGA), Stillbirth, Bacteriuria (Asymptomatic) in Pregnancy
NICHD Global Network for Women's and Children's Health
Phase 3
1,134
Belagavi, Nagpur
2025-12-08
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Guntur, Hubli, Hyderabad, Kanpur
2025-12-01
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
Novartis Pharmaceuticals
Phase 3
300
Belagavi, Mumbai, Nashik, Bikaner
2025-10-03
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Rows per page Showing 1–25 of 91
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/belagavi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.